Does NOVN.SW pay a dividend?

The cached stock data on this page does not show a positive dividend yield for NOVN.SW. Dividend status can change, so verify the latest company filings before relying on income assumptions.

What does NOVN.SW stock do?

Pure-play innovative pharmaceuticals company focused on core therapeutic areas: Oncology, Cardiovascular/Renal/Metabolic, Immunology, Neuroscience, and Radioligand Therapy following the Sandoz spinoff.

What is NOVN.SW stock's price target?

This cached page does not contain a precise model fair value for NOVN.SW.

Is NOVN.SW stock a buy?

The TradeMates model verdict for NOVN.SW is BUY with an investment score of 66/100. Treat this as a model signal to review, not a personal buy recommendation.

Is NOVN.SW a good dividend stock?

NOVN.SW is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

NOVN.SW (NOVN.SW) Stock Analysis

Q: Is NOVN.SW stock a good investment?

The cached TradeMates AI model rates NOVN.SW as BUY with an investment score of 66/100. Novartis demonstrates robust fundamental performance with revenue reaching CHF 56.67B and operating income rising to CHF 17.64B in 2025. With a P/E of 16.08x and FCF yield of 7.0%, the model identifies an attractive entry zone following recent technical pullbacks. This is algorithmic model output, not personal investment advice.

Verdict: BUY

Expanding operating margins (31.1%) and CHF 15.2B FCF support steady multi-year returns, offset by patent cliff risks on core therapies.

Investment score: 66/100

Novartis demonstrates robust fundamental performance with revenue reaching CHF 56.67B and operating income rising to CHF 17.64B in 2025. With a P/E of 16.08x and FCF yield of 7.0%, the model identifies an attractive entry zone following recent technical pullbacks.

View the full interactive analysis